nach oben

Erschienen in:

01.07.2009 | Clinical trial

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

verfasst von: Giuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, Luca Bottiglieri, Emilia Montagna, Alberto Luini, Paolo Veronesi, Mattia Intra, Rosalba Torrisi, Anna Cardillo, Elisabetta Campagnoli, Aron Goldhirsch, Marco Colleoni

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Invasive ductal carcinomas (IDC) of the breast with the triple negative phenotype (steroid hormone receptor absent, negative HER2 status) are characterized by poor clinical outcome. Additional tumor markers might allow identification of patients at higher risk. We evaluated clinical and biological features of 284 consecutive patients with pT1-3, pN1-3 M0 triple-negative IDC. Median follow-up was 70 months (interquartile range 59–94 months). Statistically significant worse disease-free and overall survival were observed in multivariate analysis, for patients with EGFR immunoreactivity in ≥50% invasive tumor cells (HR 2.39, 95% CI, 1.32–4.34, P = 0.004 for DFS; HR 2.34, 95% CI, 1.20–4.59 P = 0.01 for OS). Age ≥ 70 years and PVI were additional independent predictors of reduced overall survival. EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093 PubMedCrossRef

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098 PubMedCrossRef

Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537–544. doi:10.1016/j.molmed.2006.09.004 PubMedCrossRef

Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661–671. doi:10.1002/path.1559 PubMedCrossRef

Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271. doi:10.1038/modpathol.3800528 PubMedCrossRef

Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350. doi:10.1002/ijc.21004 PubMedCrossRef

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32. doi:10.1002/cncr.22381 PubMedCrossRef

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. doi:10.1158/1078-0432.CCR-06-3045 PubMedCrossRef

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374. doi:10.1158/1078-0432.CCR-04-0220 PubMedCrossRef

10.

McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. doi:10.1007/s10549-006-9242-8 PubMedCrossRef

11.

Japaze H, Emina J, Diaz C, Schwam RJ et al (2005) ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 14:3–10. doi:10.1016/j.breast.2004.06.003 PubMedCrossRef

12.

Azoulay S, Laé M, Fréneaux P, Merle S et al (2005) KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 8:1623–1631

13.

Orlando L, Renne G, Rocca A et al (2005) Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 16:1094–1099. doi:10.1093/annonc/mdi213 PubMedCrossRef

14.

Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553. doi:10.1056/NEJMoa012782 PubMedCrossRef

15.

Gennari R, Curigliano G, Rotmensz N et al (2004) Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 101:1302–1310. doi:10.1002/cncr.20535 PubMedCrossRef

16.

Goldhirsch A, Wood WC, Senn HJ et al (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445. doi:10.1093/jnci/87.19.1441 PubMedCrossRef

17.

Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608. doi:10.1093/jnci/90.21.1601 PubMedCrossRef

18.

Colleoni M, Liman HJ, Castiglione-Gertsch M et al (2002) Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86:1705–1714. doi:10.1038/sj.bjc.6600334 PubMedCrossRef

19.

Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B 15. J Clin Oncol 8:1483–1496PubMed

20.

Levine MN, Bramwell VH, Pritchard KL et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16:2651–2658PubMed

21.

Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349:1864–1867. doi:10.1016/S0140-6736(97)01004-0 PubMedCrossRef

22.

Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C Histopathology 41(3A):154–161. doi:10.1046/j.1365-2559.2002.14691.x CrossRef

23.

Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC

24.

Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197–202. doi:10.1097/00000478-200002000-00005 PubMedCrossRef

25.

Colleoni M, Orvieto E, Nolè F et al (1999) Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35:574–579. doi:10.1016/S0959-8049(99)00005-2 PubMedCrossRef

26.

Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729–735. doi:10.1136/jcp.2005.033043 PubMedCrossRef

27.

Ribeiro-Silva A, Ramalho LN, Garcia SB et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466. doi:10.1111/j.1365-2559.2005.02249.x PubMedCrossRef

28.

Cleator S, Heller W, Coombes RC et al (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244. doi:10.1016/S1470-2045(07)70074-8 PubMedCrossRef

29.

Goldhirsch A, Wood WC, Gelber RD (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144. doi:10.1093/annonc/mdm271 PubMedCrossRef

30.

Nieto Y, Nawaz F, Jones RB et al (2007) Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25:4405–4413. doi:10.1200/JCO.2006.09.8822 PubMedCrossRef

31.

Cheang MCU, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi:10.1158/1078-0432.CCR-07-1658 PubMedCrossRef

32.

Guix M, s Granja N, Meszoely I et al (2008) Short preoperative treatment with Erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancer. J Clin Oncol 26:897–906. doi:10.1200/JCO.2007.13.5939 PubMedCrossRef

33.

Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18

34.

Stendahl M, Ryden L, Nordenskjold B (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614–4618. doi:10.1158/1078-0432.CCR-06-0248 PubMedCrossRef

35.

Khalifa MA, Rowsell CH, Gladdy RA, Ko YJ, Hanna S, Smith A et al (2006) Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol 125:229–233PubMed

36.

Hirsch FR, Dziadzuszko R, Thatcher N et al (2008) Epidermal growth factor receptor immunohistochemistry. Cancer 112:1114–1121. doi:10.1002/cncr.23282 PubMedCrossRef

37.

Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small cell lung cancer carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 1521:3798–3807CrossRef

38.

Torrisi R, Rotmensz N, Bagnardi V et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339–2344. doi:10.1016/j.ejca.2007.07.033 PubMedCrossRef

39.

Dellapasqua S, Colleoni M, Castiglione M et al (2007) New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist 12:952–959. doi:10.1634/theoncologist.12-8-952 PubMedCrossRef

40.

Colleoni M, Rotmensz N, Maisonneuve P et al (2007) Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 18:1632–1640. doi:10.1093/annonc/mdm268 PubMedCrossRef

41.

Van de Rijn M, Perou CM, Tibshirani R et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996PubMed

42.

Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al (2007) Basal like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9:R16. doi:10.1186/bcr1649 PubMedCrossRef

43.

Colpaert C, Vermeulen P, Jeuris W et al (2001) Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumours. J Pathol 193:442–449. doi:10.1002/path.829 PubMedCrossRef

44.

Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22–34. doi:10.1111/j.1365-2559.2006.02453.x PubMedCrossRef

45.

Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35. doi:10.1038/modpathol.3800255 PubMedCrossRef

46.

Siziopikou KP, Cobleigh M (2007) The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16:104–107. doi:10.1016/j.breast.2006.09.003 PubMedCrossRef

Titel: Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
verfasst von: Giuseppe Viale
Nicole Rotmensz
Patrick Maisonneuve
Luca Bottiglieri
Emilia Montagna
Alberto Luini
Paolo Veronesi
Mattia Intra
Rosalba Torrisi
Anna Cardillo
Elisabetta Campagnoli
Aron Goldhirsch
Marco Colleoni
Publikationsdatum: 01.07.2009
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0206-z

Springer Medizin

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research

Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal–epithelial interactions

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition

Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant

Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie